Nducted a phase II trial in 27 patients. Eighteen of 27 sufferers had
Nducted a phase II trial in 27 patients. Eighteen of 27 patients had an sophisticated and RAI-refractory DTC and were administered with gefitinib (250 mg/day orally). The extra reported AEs…